acridines has been researched along with Lung Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bierbach, U; Ding, S; Hackett, CL; Hackett, RG; Liu, F | 1 |
| Błaszczak-Świątkiewicz, K; Mikiciuk-Olasik, E; Olszewska, P; Szymański, J; Szymański, P | 1 |
2 other study(ies) available for acridines and Lung Adenocarcinoma
| Article | Year |
|---|---|
Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.
Topics: A549 Cells; Acridines; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Proliferation; Drug Compounding; Drug Screening Assays, Antitumor; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Neoplasms, Experimental; Organoplatinum Compounds; Platinum | 2021 |
Novel tetrahydroacridine derivatives inhibit human lung adenocarcinoma cell growth by inducing G1 phase cell cycle arrest and apoptosis.
Topics: Acridines; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; G1 Phase Cell Cycle Checkpoints; Growth Inhibitors; Humans; Lung Neoplasms | 2014 |